Accelerated Restoration of Ocular Surface Health in Dry Eye Disease by Self-Retained Cryopreserved Amniotic Membrane.
Accelerated Restoration of Ocular Surface Health in Dry Eye Disease by Self-Retained Cryopreserved Amniotic Membrane.
复制标题
DOI：
10.1016/j.jtos.2015.07.003
复制
发表时间：
2016-01
期刊：
影响因子：
--
通讯作者：
Tseng SC
中科院分区：
文献类型：
--
作者：
Cheng AM;Zhao D;Chen R;Yin HY;Tighe S;Sheha H;Casas V;Tseng SC
评价自留冻存羊膜治疗干眼症的临床疗效。对 10 名接受自留冷冻羊膜（PROKERA® Slim [PKS]，Bio-Tissue，迈阿密，佛罗里达州）治疗的 10 名患者进行回顾性审查，这些患者对传统最大程度的药物治疗无效的中度至重度干眼症。比较治疗前后患者的症状、药物使用、结膜炎症、角膜染色和视力。 PKS 被放置在 10 名患者的 15 只眼睛中，持续 4.9 ± 1.5 天。所有患者的症状均在 4.2 ± 4.7 个月内得到缓解 (p<.001)。这种改善伴随着 OSDI 评分的降低 (p<.001)、局部药物的使用 (p<.001)、结膜充血 (p<.001)、角膜染色 (p<.001) 和视力的改善 (p=.06)。线性回归分析估计，PKS 放置的最佳持续时间为 5 天，以实现干眼患者平均无症状持续时间 4 个月。令人惊讶的是，PKS 放置也使对侧眼睛得到改善。这项初步研究表明，通过 PKS 自保留冷冻保存羊膜可用于治疗中度干眼病，并值得进一步的前瞻性对照研究。
To evaluate the clinical efficacy of self-retained cryopreserved amniotic membrane in treating dry eye disease. Retrospective review of 10 patients treated with self-retained cryopreserved amniotic membrane (PROKERA® Slim [PKS], Bio-Tissue, Miami, FL) for moderate-to-severe dry eye refractory to conventional maximal medical treatments. Patients’ symptoms, use of medications, conjunctival inflammation, corneal staining, and visual acuity were compared before and after treatment. PKS was placed in 15 eyes of the 10 patients for 4.9 ± 1.5 days. All patients experienced symptomatic relief for a period of 4.2 ± 4.7 months (p<.001). Such improvement was accompanied by reduction of OSDI scores (p<.001), use of topical medications (p<.001), conjunctival hyperemia (p<.001), corneal staining (p<.001), and improvement of the visual acuity (p=.06). Linear regression analysis estimated that the optimal duration of PKS placement was 5 days to achieve an average symptom-free duration of 4 months in patients with dry eye. Surprisingly, PKS placement also generated improvement in the contralateral eyes. This pilot study suggests that self-retained cryopreserved amniotic membrane via PKS can be used to treat moderate dry eye diseases and warrants further prospective controlled studies.